Nurse Well-Being When Health Care Is Woven in Our Family Fabric, We Find Support in Unexpected Places March 07, 2024
Nursing Professional Development OCN® Certification Test-Taking Tips to Ease Your Anxiety February 15, 2024
Oncology Nurse-Patient Relationship Oncology Nurses Help Patient Find Her Music Again December 22, 2023
Interprofessional Teams Holiday Traditions Contribute to a Positive Workplace Culture December 15, 2023
Topic Gynecological Cancers U.S. Food and Drug Administration (FDA) FDA Approves Pembrolizumab With Chemotherapy for Primary Advanced or Recurrent Endometrial Carcinoma On June 17, 2024, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda®) with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult patients with primary advanced or recurrent endometrial carcinoma. June 17, 2024 Trending Topics Research Safety Nurse Well-Being ONS Congress Drug Reference Sheets Specific Populations Clinical Practice U.S. Food and Drug Administration (FDA) Health Policy Immunotherapy View All Topics
U.S. Food and Drug Administration (FDA) FDA Approves Pembrolizumab With Chemotherapy for Primary Advanced or Recurrent Endometrial Carcinoma On June 17, 2024, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda®) with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult patients with primary advanced or recurrent endometrial carcinoma. June 17, 2024